Diabetes is a chronic condition characterized by hyperglycemia, or elevated blood glucose levels. If left untreated, diabetes may lead to complications such as cardiovascular disease, chronic renal failure, retinopathy and amputations.

Type 2 diabetes (T2DM) is a progressive disease characterized by impaired ß cell function and insulin resistance. There are over 340 million type 2 diabetics worldwide with an economic burden of close to half a trillion dollars annually.

Orally administered insulin should bring with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.

Oramed’s oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications.